News and Developments

news and developments

Press Releases

Xylonix and Invitrocue Form Strategic Clinical Alliance to Validate New Method for Combating IL-6 Pathologies

28 April 2026

“This partnership addresses a critical gap in the management of IL-6 pathologies common in cancer,
autoimmune conditions, and Long COVID”

EukairosCell, Invitrocue, Genecast and Xylonix to Launch Korea’s First IVD Lab for Advanced Cancer Treatment Diagnostics

[5 August 2025]

“This collaboration brings together cutting-edge diagnostic technologies… to deliver highly accurate, real-time cancer tracking and personalized treatment solutions”

Xylonix Secures Exclusive Distribution Rights for Invitrocue’s Onco-PDO and ADPS Cancer Diagnostics in Korea and Japan

[29 July 2025]

“The partnership will deliver Real-Time Cancer Adaptive Program to cancer patients across Korea and Japan”

Invitrocue and Genecast bring Real-time Personalized Adaptive Treatment to Cancer patients

[17 June 2025]

“Combining Onco-PDO and Ultrasenstive ADPS delivers unmatched Precision, Ultra-sensitive Detection, and is Fast and Accessible”

Xylonix and LysinBio to Combat Disease X of Bacterial Origin

[18 November 2024]

“…to focus beyond viruses – readying for deadlier bacterial Disease X with super antibacterials and nasal sprays”

Xylonix and Genecast to Transform Cancer Metastasis Research

[31 October 2024]

“New Ultra-Sensitive Blood Test to Accelerate Metastasis Studies from Months to Weeks”

Xylonix Study Reveals Link Between COVID-19 and Non-COVID-19 Excess Deaths

[December 2023]

“…up to 76% of the Non-COVID-19 excess deaths could be explained by Long COVID-patterns.”

Duke-NUS, Xylonix to improve effectiveness of Xylonix cancer drugs

[October 2021]

“New drug formulations aim to improve the in vivo circulation of Xylonix’s novel immunotherapies for treating both cancer and complications arising from COVID-19 infection.”